11 Turman Management Of Acute Renal Failure In Picu

Management of Acute Renal Failure Martin Turman, MD, PhD

Acute Renal Failure ,[object Object],[object Object],[object Object],[object Object]

ARF: Causes and mortality ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Extrarenal causes of ARF: 67% of total ,[object Object],[object Object],Data pooled from Ped. Nephrol. 7:703, 8:334, 6:470, and 7:434

ARF: Risk factors for mortality ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Best cure is to prevent ,[object Object],[object Object]

Anticipate problems ,[object Object],[object Object],[object Object],[object Object]

Case #1 ,[object Object],[object Object],[object Object]

How do you proceed from here? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Prerenal azotemia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Prerenal azotemia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Postrenal Failure ,[object Object],[object Object],[object Object],[object Object],[object Object]

Intrinsic Acute Renal Failure ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Evaluation of ARF - 1 ,[object Object],[object Object]

Evaluation of ARF - 2 ,[object Object],[object Object],[object Object],[object Object]

Evaluation for ARF - 3 ,[object Object],[object Object],[object Object],[object Object],[object Object]

Urinary indices in ARF 40 U/P Cr 20 PR ATN FE-Na 1% 2% FE-Na = (U/P Na ÷ U/P Creatinine ) *100 Adopted from J. Crit. Illness 4:32 500 U-osm 350 PR ATN 40 U-Na 20 PR ATN PR ATN

Use of FE-Na ,[object Object],[object Object],[object Object]

Back to Case #1 (intussuception) ,[object Object],[object Object],[object Object]

Clinical Case #2 ,[object Object],[object Object],[object Object],[object Object],[object Object]

Assessment of case #2 ,[object Object],[object Object],[object Object]

Use of plasma BUN: Cr ratio ,[object Object],[object Object]

Clinical Case #3 ,[object Object],[object Object],[object Object]

Physical exam and labs ,[object Object],[object Object],[object Object]

Fluid management in ARF ,[object Object],[object Object],[object Object],[object Object]

Management of ARF - Volume status ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hypertension ,[object Object],[object Object],[object Object],[object Object]

Back to Case #3 (nephritis) ,[object Object],[object Object],[object Object],[object Object]

Hyperkalemia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hyperkalemia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hypocalcemia and hyperphosphatemia ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Hypocalcemia and hyperphosphatemia ,[object Object],[object Object],[object Object]

Acidosis ,[object Object],[object Object],[object Object],[object Object],[object Object]

Anemia and uremic bleeding ,[object Object],[object Object],[object Object]

Indications for renal replacement therapy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Modes of renal replacement therapy ,[object Object],[object Object],[object Object]

Unproven or controversial treatments ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Unproven or controversial treatments ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Effect of low-dose Dopamine on ARF Adopted from Alkhunaizi & Schrier, Am J Kidney Dis 28:315

Are there any new treatments? ,[object Object],[object Object]

New potential therapies ,[object Object],[object Object],[object Object],[object Object],[object Object]

New potential therapies ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

"The great tragedy of Science - the slaying of a beautiful hypothesis by an ugly fact." T.H. Huxley (1825-1895) Collected Essays

11 Turman Management Of Acute Renal Failure In Picu

Recommandé

Recommandé

Contenu connexe

Tendances

Tendances (20)

Similaire à 11 Turman Management Of Acute Renal Failure In Picu

Similaire à 11 Turman Management Of Acute Renal Failure In Picu (20)

Plus de Dang Thanh Tuan

Plus de Dang Thanh Tuan (20)

Dernier

Dernier (20)

11 Turman Management Of Acute Renal Failure In Picu